Cardiolife Appoints New Chief Medical Officer
Cardiolife is pleased to announce the appointment of Dr. Sergio Ramalho as the company’s new Chief Medical Officer (CMO), strengthening Cardiolife’s clinical leadership as it advances its medical strategy and global product development.
Dr. Ramalho is a leading clinical and exercise cardiologist with extensive experience in both patient care and cardiovascular research. He holds an MBA in Healthcare, a PhD in Health Sciences and Technologies, and completed a Research Fellowship at Harvard Medical School. He is a Fellow of the American College of Cardiology and the European Society of Cardiology, reflecting his deep engagement in the global cardiology community. He currently serves as a senior cardiologist and professor at Hospital Sírio-Libanês in Brasília, one of Latin America’s most respected medical institutions.
Commenting on his appointment, Dr. Ramalho shared:
“I am honored to join Cardiolife at such a defining moment in its journey. The team’s dedication to scientific rigor, clinical impact, and technological excellence resonates strongly with me. I look forward to contributing to Cardiolife’s mission and supporting the advancement of innovative, AI-driven cardiac care.”
In this role, Dr. Ramalho will provide strategic leadership in medical affairs, support research and clinical initiatives, contribute to product development, and serve as a key liaison with clinicians, partners, and healthcare systems worldwide.
Cardiolife CEO Kristin Lied highlights the importance of the new CMO role:
“We are thrilled to welcome Sergio to Cardiolife. His clinical excellence, scientific depth, and practical understanding of cardiovascular diagnostics will be invaluable as we continue to scale and validate our technology internationally. After working closely with Sergio in recent months, we are confident that he brings exactly the medical leadership we need to strengthen our strategy and support our global ambitions.”
Dr. Ramalho’s unique combination of frontline clinical experience, academic research, and insight into healthcare innovation provides Cardiolife with a strong medical foundation as it advances toward FDA clearance, and broader market expansion.